Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Literature DB >> 33143518

How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

R Andrew Harkins¹, Christopher R Flowers².

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2020 PMID： 33143518 PMCID： PMC7959248 DOI： 10.1080/10428194.2020.1837798

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

Keyword Cloud
References

× No keyword cloud information.

19 in total

1. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.

Authors: Sabine Vogler; Agnes Vitry; Zaheer-Ud-Din Babar
Journal: Lancet Oncol Date: 2015-12-04 Impact factor: 41.316

2. Actual costs of cancer drugs in 15 European countries.

Authors: Wim H van Harten; Anke Wind; Paolo de Paoli; Mahasti Saghatchian; Simon Oberst
Journal: Lancet Oncol Date: 2015-12-04 Impact factor: 41.316

3. Price, value, and the cost of cancer drugs.

Authors: Tito Fojo; Andrew W Lo
Journal: Lancet Oncol Date: 2015-12-23 Impact factor: 41.316

Review 4. Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

Authors: R Andrew Harkins; Sharvil P Patel; Christopher R Flowers
Journal: Cancer J Date: 2019 Nov/Dec Impact factor: 3.360

5. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Authors: Lisa K Hicks; Harriet Bering; Kenneth R Carson; Judith Kleinerman; Vishal Kukreti; Alice Ma; Brigitta U Mueller; Sarah H O'Brien; Marcelo Pasquini; Ravindra Sarode; Lawrence Solberg; Adam E Haynes; Mark A Crowther
Journal: Blood Date: 2013-12-04 Impact factor: 22.113

How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

1. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.

2. Actual costs of cancer drugs in 15 European countries.

3. Price, value, and the cost of cancer drugs.

Review 4. Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

5. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

6. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?

7. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.

8. Projections of the cost of cancer care in the United States: 2010-2020.

9. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.

10. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.